Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
bioAffinity Technologies, Inc. ( (BIAF) ) has issued an update.
bioAffinity Technologies scheduled its 2026 annual stockholder meeting for April 30, 2026 in San Antonio after an adjourned December 19, 2025 special meeting lacked quorum, and it will carry forward those proposals while requiring shareholder nominations or new business notices by February 14, 2026 in line with its bylaws. Stakeholders now have a defined timetable for governance participation, signaling the company’s intent to resolve outstanding proposals and stabilize its shareholder engagement structure ahead of the upcoming proxy disclosures.
The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies operates within the medical diagnostics sector, developing noninvasive tests that target early disease detection for lung cancer and other conditions, serving clinicians focused on improving diagnostic accuracy.
Average Trading Volume: 91,973
Technical Sentiment Signal: Sell
Current Market Cap: $5.71M
See more data about BIAF stock on TipRanks’ Stock Analysis page.